West Midlands Renal Peer Review

Slides:



Advertisements
Similar presentations
VA Dataset National Kidney Care Audit. The audit measures two distinct areas: 1. Patient Transport Aim: To make visible the variation of provision and.
Advertisements

Dialysis in AMU Dr Mary Rogerson, Nephrologist, SGH.
UK Renal Registry 16th Annual Report Figure Data completeness for key variables, stratified by first modality HD = haemodialysis; PD = peritoneal.
World population: 6.7 billion Global Prevalence Patients per million population (p.m.p.) Global View of ESRD Patients World population 1.2% ESRD~ 7% Haemodialysis7-8%
Management of children with CKD in a DGH M Shenoy Consultant Paediatric Nephrologist RMCH Nephrology for the General Paediatrician Meeting Manchester.
The future of haemodialysis in the UK RCP advanced medicine 2013 Cormac Breen Consultant Nephrologist Guy's and St Thomas' Hospitals London.
Treatment Options for End Stage Kidney Disease Dr Vipula De Silva.
UK Renal Registry 17th Annual Report Figure Data completeness for key variables, stratified by first modality DOB = date of birth; PRD = primary.
UK Renal Registry 15th Annual Report Figure One year death rate per 1,000 patient years by UK country and age group for prevalent dialysis.
Infectious Complications of PD: Peritonitis and Exit Site / Tunnel Infections Franz Schaefer Pediatric Nephrology Division Center for Pediatric and Adolescent.
Le malattie immunitarie aumentano il rischio di complicanze infettive? Gianfranca Cabiddu Divisione Nefrologia Azienda Ospedaliera Brotzu- Cagliari.
UK Renal Registry 17th Annual Report Figure 8.1. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
Vascular access The KidneyCare Audit. The challenge of vascular access – Renal National Service Framework Standard 3 “All children, young people and adults.
© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.
ANZDATA Registry Annual Report 2013 Philip Clayton CHAPTER 9 KIDNEY DONATION 2013 Annual Report - 36th Edition PERITONEAL DIALYSIS CHAPTER 6.
UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate
Scottish Renal Registry Report 2009 Published by the Information Services Division (ISD Scotland), Common Services Agency for NHSScotland, 1 South Gyle.
UK Renal Registry 17th Annual Report Figure 2.1. Prevalence rates per million population by age group and UK country on 31/12/2013.
CHAPTER 5: PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail Source: 21 st MDTR.
ANZDATA Registry Annual Report 2013 Philip Clayton CHAPTER 9 KIDNEY DONATION 2013 Annual Report - 36th Edition PAEDIATRIC CHAPTER 11.
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
Chapter 5 Peritoneal Dialysis 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Peritoneal.
UK Renal Registry 16th Annual Report Figure Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
UK Renal Registry 10th Annual Report 2007 Fig 9.1 Annual change in percentage of dialysis patients with serum phosphate < 1.8mmol/L and ≥1.1 -≤1.8mmol/L.
Providing Quality in Peritoneal Dialysis Annette Butler and Mark Denton.
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
Clinical Change Forum 28th June, 2016
UK Renal Registry 18th Annual Report
West Midlands Renal Peer Review
Fig 7.1 Median URR achieved in each renal unit
South West Home Therapies Conference
F.H. Bender, J. Bernardini, B. Piraino  Kidney International 
UK Renal Registry 16th Annual Report
Hospital admissions per patient, by modality figure 5
Chapter 2: Clinical Indicators and Preventive Care
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani
Our Vascular Access Experience
Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study  S.-Y. Li, T.-J. Chen, K.-W. Chung,
CHAPTER 5 Paediatric Renal Replacement Therapy
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis  James F. Medcalf, Kevin P.G.
Kerry Tomlinson on behalf of sponsor group
Volume 64, Pages S3-S12 (December 2003)
Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy  G. Viglino, L. Neri, S. Barbieri  Kidney.
KQuIP/UKRR Regional Day North West
CHAPTER 1 All Renal Replacement Therapy In Malaysia
West Midlands Renal Peer Review
CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition
West Midlands Renal Peer Review
UK Renal Registry 13th Annual Report
Meeting the challenges of the new K/DOQI guidelines
West Midlands Renal Peer Review
Volume 78, Issue 6, Pages (September 2010)
UK Renal Registry 14th Annual Report
F.H. Bender, J. Bernardini, B. Piraino  Kidney International 
Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.
UK Renal Registry 16th Annual Report
Volume 73, Pages S5-S17 (April 2008)
2013 Annual Report - 36th Edition
ANZDATA Registry 41st Annual Report Highlights of End Stage Kidney Disease in Australia and New Zealand Data to 31-Dec-2017.
Microbiology and outcomes of peritonitis in North America
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1  F. Illies, K.-E. Bonzel, A.-M. Wingen, K. Latta,
American Journal of Kidney Diseases
UK Renal Registry 16th Annual Report
Rajni Singhal, Janet E. Hux, Shabbir M H Alibhai, Matthew J. Oliver 
Maristela Böhlke, PhD  American Journal of Kidney Diseases 
ANZDATA Peritoneal Dialysis Report
Stock and Flow of Haemodialysis Patients Australia
Stock and Flow of Peritoneal Dialysis Patients Australia
Stock and Flow of Peritoneal Dialysis Patients Australia
Stock and Flow of Haemodialysis Patients Australia
Presentation transcript:

West Midlands Renal Peer Review Data Overview

Peritoneal Dialysis

1. Patient population at April 2017

1. Patient population at April 2017

3. Proportion achieving combined clearance >50 or Kt/V >1. 7 (i 3. Proportion achieving combined clearance >50 or Kt/V >1.7 (i.e. proportion achieving at least one of the two targets). Most recent measure prior to Apr 1st 2017

4. Proportion of patients with 24 hour combined urine volume and UF <750mls. Most recent measure prior to Apr 1st 2017

4. Proportion of patients with 24 hour combined urine volume and UF <750mls. Most recent measure prior to Apr 1st 2017

5. Rate of PD initiation within first year of dialysis – proportion of patients starting RRT

5. Rate of PD initiation within first year of dialysis – proportion of patients starting RRT, % to PD

6. Catheter insertions during Apr 2015-March 2016 inclusive

6. Catheter insertions during Apr 2015-March 2016 inclusive

7. Specific complications in those having cathether insertion April 2016-March 2017

8. Starters and finishers for 2015-2016, Number coming onto programme

HEFT UHB UHCW SATH UHNM RWT DGH 8. Starters and finishers for 2015-2016, Numbers coming off programme 2015 Unit 2015 Transplant Died Home HD Recovered Function Moved out of Area Transfer to Haemodialysis Other HEFT UHB UHCW SATH UHNM RWT DGH

HEFT UHB UHCW SATH UHNM RWT DGH 8. Starters and finishers for 2015-2016, Numbers coming off programme 2016 Unit 2016 Transplant Died Home HD Recovered Function Moved out of Area Transfer to Haemodialysis Other HEFT UHB UHCW SATH UHNM RWT DGH

HEFT UHB UHCW SATH UHNM RWT DGH 8. Starters and finishers for 2015-2016, Reason for transfer to HD 2015 Unit 2015 Transplant Died Home HD Recovered Function Moved out of Area Transfer to Haemodialysis Other HEFT UHB UHCW SATH UHNM RWT DGH

HEFT UHB UHCW SATH UHNM RWT DGH 8. Starters and finishers for 2015-2016, Reason for transfer to HD 2016 Unit 2016 Transplant Died Home HD Recovered Function Moved out of Area Transfer to Haemodialysis Other HEFT UHB UHCW SATH UHNM RWT DGH

9. Peritonitis rate (April 2016-March 2017 data), Episodes per patient days

9. Peritonitis rate (April 2016-March 2017 data), Peritonitis Outcome, Q1 2016

9. Peritonitis rate (April 2016-March 2017 data), Peritonitis Outcome, Q2 2016

9. Peritonitis rate (April 2016-March 2017 data), Peritonitis Outcome, Q3, 2016

9. Peritonitis rate (April 2016-March 2017 data), Peritonitis Outcome, Q4 2016

9. Peritonitis rate (April 2016-March 2017 data), Peritonitis Outcome, Q1 2017

10. Exit site infections over last year (April 2016-March 2017 data) Q1 2016

10. Exit site infections over last year (April 2016-March 2017 data) Q2 2016

10. Exit site infections over last year (April 2016-March 2017 data) Q3 2016

10. Exit site infections over last year (April 2016-March 2017 data) Q4 2016

10. Exit site infections over last year (April 2016-March 2017 data) Q1 2017

11. Number of EPS patients over last 5 years